Danaher Corporation (DHR) Stock Price Today
Aura AI Summary
Key Stats
- $143.94BMarket Cap
- -Volume
- HealthSector
- $242.0552W High
- $161.9152W Low
- -Typical Hold Time
- $166.15BEnterprise Value
- 0.78%Div Yield
- -Trading Activity
Track Danaher Corporation (DHR) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Danaher Corporation has traded between a low of $161.91 and a high of $242.05, highlighting its annual price range. Buy and sell Danaher Corporation shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Most Recent News
Quadient recognized in Forrester Wave for its Accounts Payable Invoice Automation software in 2026
Quadient has been named among the leading providers in The Forrester Wave™: Accounts Payable Invoice Automation Software, Q2 2026, marking its first inclusion in this key industry evaluation. The recognition highlights Quadient's growing presence and...
Paramount Resources aims to double production by 2027, boosting cash flow with strong gas and oil prices.
Paramount Resources plans to double its average production rate by the end of fiscal year 2027, driven by a large natural gas project and recent wells exceeding expectations. The company is considering accelerating the expansion of its Alhambra plant...
ImmuPharma appoints Kymos as bioanalytical partner for diabetes drug Kapiglucagon development
ImmuPharma has appointed Kymos Group as the bioanalytical partner for its diabetes drug candidate Kapiglucagon, completing its outsourced development team. Kymos will develop and validate methods to measure the drug in biological samples and analyze ...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.